HONG KONG – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. has filed an IPO with the Hong Kong Stock Exchange (HKEX), making it the latest pre-revenue applicant for listing on the HKEX, which already has seven pre-profit biotech players listed.